Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Goodwill & Intangibles (2023 - 2025)

Tarsus Pharmaceuticals has reported Goodwill & Intangibles over the past 3 years, most recently at $7.4 million for Q4 2025.

  • Quarterly results put Goodwill & Intangibles at $7.4 million for Q4 2025, down 11.53% from a year ago — trailing twelve months through Dec 2025 was $7.4 million (down 11.53% YoY), and the annual figure for FY2025 was $7.4 million, down 11.53%.
  • Goodwill & Intangibles for Q4 2025 was $7.4 million at Tarsus Pharmaceuticals, down from $7.6 million in the prior quarter.
  • Over the last five years, Goodwill & Intangibles for TARS hit a ceiling of $8.6 million in Q3 2024 and a floor of $3.7 million in Q2 2024.
  • Median Goodwill & Intangibles over the past 3 years was $7.5 million (2025), compared with a mean of $6.3 million.
  • Biggest five-year swings in Goodwill & Intangibles: surged 115.96% in 2024 and later decreased 11.53% in 2025.
  • Tarsus Pharmaceuticals' Goodwill & Intangibles stood at $3.9 million in 2023, then skyrocketed by 115.31% to $8.3 million in 2024, then dropped by 11.53% to $7.4 million in 2025.
  • The last three reported values for Goodwill & Intangibles were $7.4 million (Q4 2025), $7.6 million (Q3 2025), and $7.8 million (Q2 2025) per Business Quant data.